NIAID researchers describe a Phase 2 trial showing that an experimental chikungunya vaccine is both safe and well-tolerated.

Friday, April 17, 2020 Experimental Chikungunya Vaccine is Safe and Well-Tolerated in Early Trial The chikungunya virus, which is found throughout tropical areas of the world, can cause intense pain and joint inflammation. Unfortunately, this mosquito-borne virus currently has no cure or vaccine. In a paper published this week in JAMA, NIAID researchers describe a Phase 2 trial showing that an experimental chikungunya vaccine is both safe and well-tolerated, and shows promise for future trials.  National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107